To report a rare case of sodium valproate (VPA)-induced reversible myelodysplastic syndrome (MDS) in a pediatric patient, thereby expanding the recognition of VPA-associated hematological toxicity in children.
Key Findings:
The patient developed MDS after 6 months of VPA therapy, highlighting the need for monitoring.
Reduction of VPA dose led to normalization of hematological parameters within 3 months.
A repeat bone marrow examination revealed resolution of dysplastic features, indicating reversibility.
Interpretation:
The case highlights the dose-dependent nature of VPA-induced MDS and its reversibility upon therapeutic intervention.
Limitations:
The study is based on a single case report, limiting generalizability.
Monthly hematological monitoring was not performed due to logistical challenges, which may affect the reliability of the findings.
Conclusion:
The reversibility of VPA-induced MDS following dose adjustment underscores the importance of vigilant hematological monitoring in children.
